{"id":"W4310183164","doi":"10.1159/000528272","title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Sorafenib; Bevacizumab; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Hazard ratio; Oncology; Liver cancer; Cancer; Phases of clinical research; Gastroenterology; Confidence interval; Chemotherapy; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003344452,0.0009010899,0.001566201,0.0003239188,0.0001793731,0.000994458,0.0007400393,0.0006122946,0.001732347],"category_scores_gemma":[0.001895525,0.0004426027,0.00239457,0.0003355182,0.0004791543,0.0006745421,0.0004256689,0.001651599,0.0004933018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000953678,"about_ca_system_score_gemma":0.001064719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005260748,"about_ca_topic_score_gemma":0.001572053,"domain_scores_codex":[0.9988417,0.0007761745,0.0000640716,0.0001350837,0.00009267935,0.00009031606],"domain_scores_gemma":[0.9986256,0.0003214227,0.0004434824,0.0001193087,0.0000961781,0.0003939637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9063448,0.01218255,0.01745506,0.0005785669,0.004056783,0.000107621,0.0001512854,0.001722483,0.01002335,0.0001251178,0.001561293,0.04569114],"study_design_scores_gemma":[0.5474781,0.3766801,0.06389563,0.00007872999,0.003157036,0.0003274144,0.0000856793,0.00315738,0.002750948,0.0001990633,0.002132975,0.00005687651],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956157,0.002091164,0.0003113906,0.0002191141,0.00003725541,0.0004248618,0.0005458057,0.00003757369,0.0007171386],"genre_scores_gemma":[0.9966354,0.0005364902,0.0005243206,0.0002687312,0.00006208057,0.000382223,0.001157906,0.00001087466,0.0004220627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003344452,"threshold_uncertainty_score":0.01768732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06051174997819984,"score_gpt":0.2949862541609207,"score_spread":0.2344745041827209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}